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Abstract: Background An increase in transvalvular pressure gradient of prosthetic valve should always
raise suspicion for obstructive valve thrombosis. A multimodality diagnostic approach including transtho-
racic echocardiography, transoesophageal echocardiography (TOE), cinefluoroscopy, or computed tomog-
raphy (CT) is necessary for a prompt diagnosis. The management of mechanical prosthetic valve throm-
bosis (PVT) is high risk in any therapeutic option taken. Emergency valve replacement is recommended
for critically ill patients. Fibrinolysis is an alternative for patients with contraindication to surgery or
if surgery is not immediately available. Case summary A 52-year-old woman presented with symptoms
and signs of cardiac congestion. On laboratory, brain natriuretic peptide was elevated and international
normalized ratio (INR) was in subtherapeutic range. She underwent a mitral valve replacement with
mechanical prosthesis 7 months before, because of a significant residual regurgitation after repair on the
same year. TOE revealed severe stenosis of the prosthesis with immobile anterior disc but there was
no mass present. CT revealed a minor lesion at the hinge points of the prosthesis without involvement
of the ring, suggestive for thrombus. The initial fruitless management with intravenous (i.v) heparin
in high therapeutic range was followed by a successful ’low-dose, ultra-slow’ fibrinolysis. Discussion CT
may help differentiate thrombus vs. pannus. The acute onset of symptoms, inadequate anticoagulation,
and restricted leaflet motion increased the suspicion for PVT. The current European guidelines propose
normal dose fibrinolysis. We performed ’low-dose, ultra-slow’ fibrinolysis due to lower bleeding risk with
successful results. Low dose should be considered as alternative to normal dose fibrinolysis or urgent
surgery.
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Background An increase in transvalvular pressure gradient of prosthetic valve should always raise suspicion for obstructive
valve thrombosis. A multimodality diagnostic approach including transthoracic echocardiography, transoesophageal
echocardiography (TOE), cinefluoroscopy, or computed tomography (CT) is necessary for a prompt diagnosis. The
management of mechanical prosthetic valve thrombosis (PVT) is high risk in any therapeutic option taken.
Emergency valve replacement is recommended for critically ill patients. Fibrinolysis is an alternative for patients
with contraindication to surgery or if surgery is not immediately available.
...................................................................................................................................................................................................
Case summary A 52-year-old woman presented with symptoms and signs of cardiac congestion. On laboratory, brain natriuretic
peptide was elevated and international normalized ratio (INR) was in subtherapeutic range. She underwent a mitral
valve replacement with mechanical prosthesis 7months before, because of a significant residual regurgitation after
repair on the same year. TOE revealed severe stenosis of the prosthesis with immobile anterior disc but there was
no mass present. CT revealed a minor lesion at the hinge points of the prosthesis without involvement of the ring,
suggestive for thrombus. The initial fruitless management with intravenous (i.v) heparin in high therapeutic range
was followed by a successful ‘low-dose, ultra-slow’ fibrinolysis.
...................................................................................................................................................................................................
Discussion CT may help differentiate thrombus vs. pannus. The acute onset of symptoms, inadequate anticoagulation, and
restricted leaflet motion increased the suspicion for PVT. The current European guidelines propose normal dose fi-
brinolysis. We performed ‘low-dose, ultra-slow’ fibrinolysis due to lower bleeding risk with successful results. Low
dose should be considered as alternative to normal dose fibrinolysis or urgent surgery.
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Learning points
• CT should be performed to differentiate pannus vs. thrombus if no mass is detected during transoesophageal echocardiography.
• Low-dose, ultra-slow fibrinolysis should be considered as an alternative to normal dose fibrinolysis or urgent surgery.
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Every replacement of a diseased heart valve with either biological or
mechanical prosthesis exchanges the native disease for prosthesis-
related complications. The most common complications include
prosthetic valve obstruction, embolic events, bleeding, infective
endocarditis, and haemolysis. An obstruction may be caused by
thrombosis and/or pannus formation. A prosthetic valve thrombosis
(PVT) can be symptomatic or subclinical (non-obstructive).
Prosthetic valve obstruction is defined as an increase in the mean
gradient on steady-state haemodynamic condition, estimated with
transthoracic echocardiography (TTE), above the expected normal
range for the specific type and size of the prosthesis. The reported in-
cidence of symptomatic obstructive mechanical prosthesis ranges
from 0.3% to 1.3% per year, with subtherapeutic anticoagulation
been the major risk factor.1,2Mitral mechanical PVT is reported to be
twice as frequent as aortic mechanical PVT and rates of thrombo-
embolism are higher for certain types of mechanical valves. PVT
should be suspected in a patient with a new murmur, change in clos-
ing clicks, symptoms, and signs of heart failure or thromboembolic
events. The initial evaluation is performed with TTE and additional
imaging options include transoesophageal echocardiography (TOE),
cardiac computed tomography (CT) or fluoroscopy. The choice be-
tween TOE and CT as additional imaging tools is made based upon
availability, patient characteristics, prior test results, mechanical valve
type/location, and local expertise.2
Timeline
Case presentation
A 52-year-old woman presented to the emergency department with
dyspnoea, chest pain, and haemoptysis. She was haemodynamically
stable (blood pressure 137/85mmHg, heart rate 85/min, respiratory
rate 22/min) with signs of cardiac congestion. The physical examin-
ation revealed mild bilateral ankle oedema with bilateral basal
crackles and a systolic click without additional heart sounds. She
underwent a mitral valve replacement with a mechanical prosthesis
(St. Jude Medical 25mm) 7months ago, because of recurrent moder-
ate to severe mitral regurgitation after mitral valve repair in the same
year due to symptomatic severe primary mitral regurgitation of
(post-)inflammatory aetiology. Her electrocardiogram and chest
X-ray were unremarkable. However, plasma N-terminal prohor-
mone of brain natriuretic peptide was significantly elevated (6944ng/L,
N<249ng/L), and her serum creatinine was 129mmol/L
(N<80mmol/L) consistent with her well-documented chronic renal
failure.
Her current pharmacological therapy on admission was
Phenprocoumon 1.5mg OD, Bisoprolol 10mg OD, Levothyroxine
0.1mg OD, Pantoprazole 40mg OD, Montelukast 10mg OD, and
Budesonide/Formoterol Inh 0.4þ 0.012mg bid. Despite being on
oral anticoagulation therapy because of mechanical mitral valve pros-
thesis, her INR was below her target range (2.3). Hs-troponin
(101ng/L, N<14ng/L) and C-reactive protein (24mg/L, N<5mg/L)
were slightly elevated.
The emergency TTE revealed a markedly elevated diastolic trans-
mitral pressure gradient of 21mmHg with impaired movement of
one of the prosthesis discs. The last documented transvalvular gradi-
ent in our institution was 4mmHg before discharge after the mitral
valve replacement (20 April 2018). Left ventricular systolic function
was normal and no mass was visualized in conjunction with the
prosthesis. However, the atrial part of the mechanical prosthesis was
not demonstrated sufficiently because of shadowing and reverber-
ation artefacts (Figure 1). Fluoroscopy revealed an immobile anterior
disc of the mitral prosthesis. Transoesophageal echocardiography
confirmed the severe stenosis of the mitral prosthesis due to an
immobile anterior disc, but no mass could be detected (Figure 2).
Based on the medical history with acute onset of symptoms, inad-
equate anticoagulation, and restricted leaflet motion we diagnosed a
PVT and initiated a therapy with diuretics and IV unfractionated
heparin. We performed a PET/CT scan that excluded inflammation
and showed a minor lesion on the atrial and ventricular side of the
septal hinge point of the mitral prosthesis without involvement of the
prosthesis ring (Figure 3). Five days after IV unfractionated heparin in
high therapeutic range the severity of the mitral stenosis remained
unchanged. Therefore, we performed a ‘low-dose, ultra-slow’ fibrino-
lytic therapy with 25mg Alteplase; a tissue plasminogen activator
(t-PA), without a bolus and with an infusion period of 25 h, as proposed
in the focused update of the Americal College of Cardiology (ACC)
guidelines for the management of valvular heart disease (2017). This fi-
brinolytic schema was repeated the day after, thus a cumulative dose
of 50mg t-PA was administered, after a pause of 15 h with unfractio-
nated heparin in therapeutic range. We decided for this treatment
because it is associated with a lower bleeding risk. The TTE per-
formed on the next day confirmed successful resolution of the
November 2017 Diagnosis of symptomatic severe mitral
regurgitation of post-inflammatory
aetiology
09 February 2018 Mitral valve reconstruction
(annuloplasty ring)
28 March 2018 Mitral valve replacement due to recurrent
moderate to severe mitral regurgitation;
restriction of the posterior leaflet
March 2018 to
April 2018
Intensive care unit stay with open chest treat-








08 October 2018 Pulmonary oedema due to mechanical valve
thrombosis
19 October 2018 Successful thrombolysis with low-dose,
ultra-slow infusion of tissue plasminogen
activator
February 2019 Normal function of the prosthesis, INR
target 3–3.5



























































































thrombus as the motion of the prosthesis discs was normal and the
diastolic pressure gradient had returned to baseline values (Figure 4).
On discharge, we intensified the oral anticoagulation with
Phenprocoumon 1.5mg setting a higher INR target range (INR 2.5–
3.5), reduced the dose of Bisoprolol to 5mg OD, and started with
Lisinopril 2.5mg OD. She remained on Levothyroxine 0.1mg OD,
Pantoprazole 40mg OD, and Montelukast 10mg OD. The antiob-
structive therapy with Budesonide/Formoterol Inh was stopped.
After discharge, the patient has been regularly seen in our out-
patient clinic. She has been doing well and has no cardiac symptoms.
Figure 1 (A) Parasternal long axis (PLAX) in transthoracic echocardiography. The atrial part of the mechanical prosthesis is not sufficiently visual-
ized due to reverberation artefacts. (B) Transmitral diastolic pressure gradient acquired form apical four chamber view (4CV) showing a severe
stenosis.
Figure 2 (A) Fluoroscopy showing the immobile anterior disk of the prosthesis. (B) Three-dimensional transoesophageal echocardiography
confirming the finding in fluoroscopy. (C) Transoesophageal echocardiography (2CV) showing the immobile anterior disk. (D) Transoesophageal
echocardiography (2CV) with colour Doppler showing the acceleration of mitral inflow suggestive of significant stenosis.









































































































































The last echocardiography was performed 4months after discharge
showing a normal function of the mitral valve prosthesis. Due to diffi-
culties in dose adjustment of oral anticoagulation therapy with
Phenprocoumon, we perform a regular control of her INR value on a
weekly basis and individually adjust the dose in correspondence with
her pharmacist in order to remain in the INR target range of 2.5–3.5.
Discussion
In order to determine the adequate therapeutic range of anticoagula-
tion in patients with mechanical valve prosthesis, not only the
thrombogenicity of the valve but also the individual thrombotic risk
of the patient should be taken into consideration. Patients with atrio-
ventricular valve prosthesis, heart failure, atrial fibrillation, or previous
thrombosis are known to be at high risk for thrombosis. The
reported incidence of symptomatic obstructive mechanical valve
thrombosis ranges from 0.3% to 1.3% per year. Although mechanical
valve thrombosis is by far more often, thrombosis of bioprosthesis
has been reported after surgery and catheter valve implantation.
Subclinical PVT is more common than symptomatic, especially when
assessed with cardiac CT.2
The clinical history may imply the underlying aetiology of dysfunc-
tion as acute onset of symptoms and history of inadequate anticoagu-
lation are highly suggestive of thrombosis.
If stenosis of a mechanical mitral prosthesis is suspected, but no
mass can be detected by TTE and/or TEE or the mobility of the pros-
thesis leaflets is not impaired, further investigation with cardiac CT is
needed in order to differentiate between pannus or thrombus.3
Computed tomography is more sensitive in detecting small lesions as
it has higher spatial resolution in comparison to TTE/TEE.
Furthermore, the localization of a lesion in combination with its signal
intensity measured in Hounsfield Units (HU) may allow the differenti-
ation between pannus and thrombus.4,5 Thrombus typically involves
the hinge points of the prosthesis and lower HU (<90) are measured,
while pannus usually involves the circumference of the prosthesis
and higher HU (>140) are expected.6
Urgent valve surgery or thrombolysis are both associated
with high morbidity and mortality.7,8 In case the patient is critically ill,
urgent valve surgery should be performed. If the surgical risk exceeds
Figure 3 (A) Computed tomography showing two small lesions on the septal hinge point of the prosthesis suggestive of small thrombi. (B) Normal
signal intensity of valve prosthesis 7months after implantation without suspicion of infective endocarditis.
Figure 4 (A) PLAX in transthoracic echocardiography after thrombolysis allowing good visualization of the disks with normal opening. (B) Apical
4CV with normalization of the transmitral diastolic pressure gradient after thrombolysis.

























































































































































































































the bleeding risk or valve surgery is not available, thrombolysis is an
alternative therapy. The European guidelines for management of
valvular heart disease propose a normal dose thrombolysis (10mg
bolusþ 90mg in 90min) with t-PA which is associated with high
bleeding and stroke risk. The focused update of the American guide-
lines recommends an alternative thrombolytic treatment algorithm
of ‘low-dose, ultra-slow’ t-PA infusion based on observational stud-
ies.9 Hence, only 25mg of t-PA without a bolus and with an infusion
period of 25 h is applied and this procedure exhibited the same effi-
cacy with lower bleeding risk. After thrombolysis, unfractionated
heparin with a target activated partial thromboplastin time (aPTT) of
1.5–2.0 times the control value is applied for 6 h and in case of recur-
rent stenosis, the regime could be repeated until a maximal dose of
200mg. Most patients are expected to require three or fewer infu-
sions and the reported success rate is up to 90% with a non-fatal
complication rate of 4% and just one case of in-hospital death.10,11
Conclusions
In the absence of mass on the prosthesis in TEE or if the mobility of
the prosthesis leaflets is not impaired, CT may improve the detection
and help the differentiation between pannus and thrombus. Low-
dose, ultra-slow fibrinolysis should be considered as an alternative to
normal dose fibrinolysis or urgent surgery.
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